Development and Implementation of COVID-19 Immune Assay(s) Development and Implementation BARDA-IEIDD-063025
Summary
AI-generated · Aug 24, 2025Provide a central laboratory capacity site to analyze mucosal and serum samples collected from subjects enrolled in multiple US government–sponsored COVID-19 vaccine trials. Use validated virus neutralization (VN) and binding assays to support these studies, with goals to establish validated VN and binding assays for SARS-CoV-2 emerging variant(s) and to test serum samples from trial participants in variant VN and binding antibody assays, all in compliance with Good Clinical Laboratory Practice (GCLP) guidelines.
This procurement is aimed at providing a central laboratory capacity site for analysis of mucosal and serum samples collected from subjects enrolled in multiple USG-sponsored COVID-19 vaccine trials. This action covers efforts to utilize the validated virus neutralization (VN) and binding assays to support these studies. The program goals are: 1. Establish validated VN and binding assays for SARS-CoV-2 emerging variant(s). 2. Test serum samples from human subjects enrolled in clinical trials of COVID-19 vaccine candidates in variant VN and binding antibody assays in compliance with GCLP guidelines.
From Justification posted on Jun 30, 2025Notice history
1Details
Award Information
Contacts
Phone
Agency
Place of Performance
USA